Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2009

View Archived Issues

Bayer Schering Pharma and AstraZeneca claim GR ligands as anti-inflammatory agents

Vasopressin V1b receptor ligands under development at Abbott

Bristol-Myers Squibb discovers new NS5B polymerase inhibitors for the treatment of HCV

Studies assess ghrelin in healthy men, frail older women, hip replacement patients

Merck Research Laboratories describes orally active very-late antigen-4 antagonists

Phase II activity of masitinib with gemcitabine in pancreatic cancer leads to phase III study

Preclinical antihypertensive activity seen with SAR-407899

Pharming presents results from final analysis of Rhucin studies

CombinatoRx and Neuromed enter into merger agreement

Pfizer discontinues phase III trial of Sutent in metastatic colorectal cancer

Inovio signs collaboration agreement with NML and UP to evaluate H1N1 vaccines

Vical reports results from two parallel animal studies of DNA vaccine against A/H1N1

Medinet and the University of Tokyo Hospital start collaborative clinical study

FDA approves Multaq for atrial fibrillation and atrial flutter

Astellas and Maxygen sign joint venture agreement for multiple protein pharmaceuticals

Amira reports initial results from phase I clinical study of AM-211 for respiratory diseases

Biogen and Acorda sign collaboration and license agreement for MS drug Fampridine-SR

FDA makes initial regulatory determination on Novartis' BLA for Menveo vaccine

BioSante and Cell Genesys sign definitive merger agreement

Study results for Intermezzo in middle-of-the-night awakenings detailed

Takeda presents further data on ramelteon efficacy in chronic insomnia

Lupin acquires worldwide rights to Collegium's AllerNaze

Chelsea Therapeutics completes enrollment in phase III trial of droxidopa in NOH

Repros scheduled to discuss phase III clinical program for Proellex with the FDA

Provectus completes patient accrual in phase II PH-10 study for atopic dermatitis